<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ljubojevic-Holzer S</submitter><funding>BioTechMed-Graz [Young Researcher Groups</funding><funding>Austrian Science Fund FWF</funding><funding>Medical University of Graz scholarship</funding><funding>European Society of Cardiology and Austrian Society of Cardiology</funding><pagination>1492-1505</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9074988</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>118(6)</volume><pubmed_abstract>&lt;h4>Aims&lt;/h4>Autophagy protects against the development of cardiac hypertrophy and failure. While aberrant Ca2+ handling promotes myocardial remodelling and contributes to contractile dysfunction, the role of autophagy in maintaining Ca2+ homeostasis remains elusive. Here, we examined whether Atg5 deficiency-mediated autophagy promotes early changes in subcellular Ca2+ handling in ventricular cardiomyocytes, and whether those alterations associate with compromised cardiac reserve capacity, which commonly precedes the onset of heart failure.&lt;h4>Methods and results&lt;/h4>RT-qPCR and immunoblotting demonstrated reduced Atg5 gene and protein expression and decreased abundancy of autophagy markers in hypertrophied and failing human hearts. The function of ATG5 was examined using cardiomyocyte-spe</pubmed_abstract><journal>Cardiovascular research</journal><pubmed_title>Loss of autophagy protein ATG5 impairs cardiac capacity in mice and humans through diminishing mitochondrial abundance and disrupting Ca2+ cycling.</pubmed_title><pmcid>PMC9074988</pmcid><funding_grant_id>V 530</funding_grant_id><funding_grant_id>P27637-B28</funding_grant_id><funding_grant_id>I3301-MINOTAUR</funding_grant_id><pubmed_authors>Kling KM</pubmed_authors><pubmed_authors>von Lewinski D</pubmed_authors><pubmed_authors>Sedej S</pubmed_authors><pubmed_authors>Nickel A</pubmed_authors><pubmed_authors>Kohlhaas M</pubmed_authors><pubmed_authors>Ljubojevic-Holzer S</pubmed_authors><pubmed_authors>Herbst V</pubmed_authors><pubmed_authors>Abdellatif M</pubmed_authors><pubmed_authors>Zirlik A</pubmed_authors><pubmed_authors>Muhlfeld C</pubmed_authors><pubmed_authors>Schmidt M</pubmed_authors><pubmed_authors>Maack C</pubmed_authors><pubmed_authors>Kraler S</pubmed_authors><pubmed_authors>Djalinac N</pubmed_authors><pubmed_authors>Schipke J</pubmed_authors><pubmed_authors>Scherr D</pubmed_authors><pubmed_authors>Voglhuber J</pubmed_authors><pubmed_authors>Franke GT</pubmed_authors><pubmed_authors>Rainer PP</pubmed_authors></additional><is_claimable>false</is_claimable><name>Loss of autophagy protein ATG5 impairs cardiac capacity in mice and humans through diminishing mitochondrial abundance and disrupting Ca2+ cycling.</name><description>&lt;h4>Aims&lt;/h4>Autophagy protects against the development of cardiac hypertrophy and failure. While aberrant Ca2+ handling promotes myocardial remodelling and contributes to contractile dysfunction, the role of autophagy in maintaining Ca2+ homeostasis remains elusive. Here, we examined whether Atg5 deficiency-mediated autophagy promotes early changes in subcellular Ca2+ handling in ventricular cardiomyocytes, and whether those alterations associate with compromised cardiac reserve capacity, which commonly precedes the onset of heart failure.&lt;h4>Methods and results&lt;/h4>RT-qPCR and immunoblotting demonstrated reduced Atg5 gene and protein expression and decreased abundancy of autophagy markers in hypertrophied and failing human hearts. The function of ATG5 was examined using cardiomyocyte-spe</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 May</publication><modification>2025-04-03T22:22:26.094Z</modification><creation>2024-12-03T23:39:17.808Z</creation></dates><accession>S-EPMC9074988</accession><cross_references><pubmed>33752242</pubmed><doi>10.1093/cvr/cvab112</doi></cross_references></HashMap>